ConductScience.org, home

Paper41007845

Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential.

Liu G and 5 others. Biomedicines, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential. Papers, record 41007845. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007845

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential.
PubMed
Journal
Biomedicines
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-09-30
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu GGeorgehttps://orcid.org/0009-0006-2414-6428
2De Vlaminck GGuillaume
3Atekha OOsayamenhttps://orcid.org/0009-0002-2605-0420
4Grewal EPEric Phttps://orcid.org/0000-0002-2189-7975
5Ramapriyan RRishabhttps://orcid.org/0000-0002-2945-3236
6Agarwal GGautam

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References174

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140214442The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis.Cells2025https://conductscience.org/library/papers/40214442PubMed
236040835Cardiovascular complications of immune checkpoint inhibitors for cancer.Eur Heart J2022https://conductscience.org/library/papers/36040835PubMed
316037567Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage.Arterioscler Thromb Vasc Biol2005https://conductscience.org/library/papers/16037567PubMed
418650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
533277608Engineering precision nanoparticles for drug delivery.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33277608PubMed
637644871Comparison of Long-Term Outcomes Between Intravascular Ultrasound-, Optical Coherence Tomography- and Angiography-Guided Stent Implantation: A Meta-Analysis.Angiology2024https://conductscience.org/library/papers/37644871PubMed
723598172Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.Lancet Oncol2013https://conductscience.org/library/papers/23598172PubMed
816160601Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis.J Cardiovasc Pharmacol2005https://conductscience.org/library/papers/16160601PubMed
923964934Pazopanib versus sunitinib in metastatic renal-cell carcinoma.N Engl J Med2013https://conductscience.org/library/papers/23964934PubMed
1027941169Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits.Hum Exp Toxicol2017https://conductscience.org/library/papers/27941169PubMed
1126371140Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.J Clin Oncol2015https://conductscience.org/library/papers/26371140PubMed
1229079346Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice.Vascul Pharmacol2018https://conductscience.org/library/papers/29079346PubMed
1330827782Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.Lancet2019https://conductscience.org/library/papers/30827782PubMed
1422451584Pulmonary arterial hypertension in patients treated by dasatinib.Circulation2012https://conductscience.org/library/papers/22451584PubMed
1525652038Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins.Aging Cell2015https://conductscience.org/library/papers/25652038PubMed
1630380386CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.N Engl J Med2018https://conductscience.org/library/papers/30380386PubMed
1738763321Altered cancer metabolism and implications for next-generation CAR T-cell therapies.Pharmacol Ther2024https://conductscience.org/library/papers/38763321PubMed
1834286881Reactive oxygen species in cancer: Current findings and future directions.Cancer Sci2021https://conductscience.org/library/papers/34286881PubMed
1936744254Natural compounds from botanical drugs targeting mTOR signaling pathway as promising therapeutics for atherosclerosis: A review.Front Pharmacol2023https://conductscience.org/library/papers/36744254PubMed
2029933080Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis.Vascul Pharmacol2019https://conductscience.org/library/papers/29933080PubMed

See all 174 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41007845

GET https://conductscience.org/api/papers/v1/41007845/references?page=2